Skip to main content
GRAFT POLYMER (UK) PLC logo

GRAFT POLYMER (UK) PLC — Investor Relations & Filings

Ticker · GPL ISIN · GB00BMD1Z199 LEI · 2138005PH7OJRCRPUD88 IL Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2026-04-29 Earnings Release
Country GB United Kingdom
Listing IL GPL

About GRAFT POLYMER (UK) PLC

https://graftpolymer.com/

GRAFT POLYMER (UK) PLC is a technology company specializing in polymer modification and the development of drug delivery systems. The company's core expertise lies in creating proprietary polymer modifiers that enable the combination of otherwise incompatible materials. This process results in cost-effective polymer alloys with enhanced mechanical characteristics, chemical resistance, and fire-retardant properties. Leveraging extensive research and development, the company provides bespoke, 'turn-key' solutions and customized products. Through its GraftBio division, the company also develops bio/pharma applications, including biological supplements and advanced drug delivery systems, supported by a strong intellectual property portfolio.

Recent filings

Filing Released Lang Actions
Final Results
Earnings Release Classification · 1% confidence The document is a public announcement of the company’s audited results for the year ended 31 December 2025, with key highlights, CEO/Chairman commentary, and summary financials, and refers readers to the full Annual Report on the website. This matches an initial earnings release for the full-year results rather than the full Annual Report itself. Therefore, it should be classified as an Earnings Release (ER). FY 2025
2026-04-29 English
Appointment of Water Tower Research
Regulatory Filings Classification · 1% confidence The document is a press release via the London Stock Exchange’s RNS service announcing the appointment of an investor‐relations/research firm. It does not present financial results (not an ER or IR), does not issue new shares or raise capital (not CAP or SHA), does not deal with governance, voting results, legal proceedings, M&A, dividends, or director dealings. It is a general corporate/market announcement distributed through RNS without fitting any more specific category. As such, it falls under the fallback “Regulatory Filings” category.
2026-04-22 English
US CNS Executive Order
Regulatory Filings Classification · 1% confidence The document is a corporate press release distributed via the London Stock Exchange’s RNS system, providing a commentary on President Trump’s Executive Order and the company’s view on regulatory developments. It is not a financial report (10-K, IR, ER), not an AGM or investor presentation, nor does it announce dividends, share transactions, M&A, board changes or regulatory/legal proceedings. It is a general regulatory announcement/fall-back press release. Therefore, it should be classified as an RNS.
2026-04-20 English
Granted U.S. Patent from PTSD Discovery Programme
Regulatory Filings Classification · 1% confidence The document is an RNS announcement of inside information regarding the grant of a U.S. patent. It is neither a financial report nor a specialized governance, capital, or dividend notice. It is a general regulatory news release distributed via the London Stock Exchange’s Regulatory News Service (RNS), fitting the fallback category for miscellaneous regulatory filings.
2026-04-08 English
Granted U.S. Patent from PTSD Discovery Programme
Regulatory Filings Classification · 1% confidence The document is a Regulatory News Service (RNS) announcement from Solvonis Therapeutics plc regarding the grant of a U.S. patent. It is a market ad-hoc release distributed via the London Stock Exchange’s RNS. It is not a financial or operational report (Annual Report, Interim Report, Earnings Release, etc.), nor does it fit specialized categories like M&A, dividends, share issues, or management changes. Therefore, it falls under the fallback category "Regulatory Filings" (RNS).
2026-03-31 English
SVN-114 selected for PTSD discovery programme
Regulatory Filings Classification · 1% confidence The document is a press release issued via the London Stock Exchange's Regulatory News Service (RNS). It announces a specific corporate development: the selection of a lead drug candidate (SVN-114) for a PTSD discovery program. It does not fit into specific categories like financial reports, dividend notices, or board changes. As it is a general regulatory announcement regarding company operations and R&D progress, it falls under the 'Regulatory Filings' (RNS) category.
2026-03-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.